Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Pliant Therapeutics to similar companies based on the strength of its valuation, profitability, institutional ownership, risk, dividends, analyst recommendations and earnings.
Insider and Institutional Ownership
97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 8.7% of Pliant Therapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Pliant Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Pliant Therapeutics’ rivals have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Pliant Therapeutics | N/A | -57.13% | -44.97% |
| Pliant Therapeutics Competitors | -12,516.26% | -215.37% | -31.41% |
Analyst Ratings
This is a breakdown of recent recommendations for Pliant Therapeutics and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pliant Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Pliant Therapeutics Competitors | 9920 | 15335 | 45741 | 1601 | 2.54 |
Pliant Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 383.87%. As a group, “Biotechnology” companies have a potential upside of 110.14%. Given Pliant Therapeutics’ higher probable upside, equities research analysts clearly believe Pliant Therapeutics is more favorable than its rivals.
Valuation and Earnings
This table compares Pliant Therapeutics and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Pliant Therapeutics | $1.58 million | -$149.34 million | -0.43 |
| Pliant Therapeutics Competitors | $690.26 million | $7.76 million | -18.38 |
Pliant Therapeutics’ rivals have higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Pliant Therapeutics rivals beat Pliant Therapeutics on 7 of the 12 factors compared.
Pliant Therapeutics Company Profile
Pliant Therapeutics is a biopharmaceutical company focused on developing medicines for fibrotic diseases, in which excess scar tissue can impair the function of organs. The company’s research centers on integrins, proteins involved in processes such as tissue repair and fibrosis. Its investigational programs have included bexotegrast, an oral drug designed to inhibit the αvβ6 and αvβ1 integrins and studied for conditions including idiopathic pulmonary fibrosis. Pliant has also pursued other drug candidates targeting fibrotic disease pathways.
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
